Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775479 | 0.85 | KDM4E (0.46) | RBP4KDM4EMAPTALDH1A1PKM | |
| SCHEMBL2393871 | 0.84 | CYP1A2 (0.47) | KDM4EMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3243181 | 0.81 | RBP4 (0.46) | RBP4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16303300 | 0.80 | NOTUM (0.47) | RBP4KDM4EMAPTALDH1A1PKM | |
| SCHEMBL23023554 | 0.80 | CBLB (0.45) | — | |
| SCHEMBL21201020 | 0.78 | MRGPRX4 (0.38) | RBP4KDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4826028 | 0.77 | KDM4E (0.50) | RBP4KDM4EMAPTALDH1A1PKM | |
| SCHEMBL21044587 | 0.75 | NOTUM (0.53) | RBP4KDM4EMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL9589167 | 0.75 | KDM4E (0.49) | RBP4KDM4EMAPTALDH1A1PKM | |
| SCHEMBL16578051 | 0.74 | KDM4E (0.48) | RBP4KDM4EMAPTALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | RBP4 3275/4885KDM4E 751/4885MAPT 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.